CRISPR Therapeutics AG (CRSP) stock forecast and price target
Price $42.24 · data as of November 13, 2026
12-month price target
Average target$85.42
Upside / downside+102.2%
Analysts19
ConsensusBuy
Low $44.00Average $85.42High $291.00
Gold marker: average target · white marker: today’s price ($42.24)
Analyst ratings
Strong buy 4Buy 9Hold 10Sell 0Strong sell 0
Earnings and revenue estimates
| Period | EPS estimate | EPS growth | Revenue estimate |
|---|---|---|---|
| Current fiscal year ends December 31, 2026 | $-4.53 | +30.0% | $35M |
| Next fiscal year ends December 31, 2027 | $-3.69 | +18.7% | $134M |
| Next quarter ends December 31, 2026 | $-1.18 | +14.0% | $13M |
| Quarter after ends March 31, 2027 | $-1.09 | +14.6% | $11M |
Consensus of the analysts covering CRISPR Therapeutics, updated daily. In the last 30 days 6 estimates were raised and 9 lowered.
Frequently asked questions
What is the CRISPR Therapeutics stock price target?
The average 12-month target from 19 analysts is $85.42, 102.2% above the current price of $42.24 Targets range from $44.00 to $291.00.
Is CRISPR Therapeutics a buy according to analysts?
The consensus rating is “Buy” (4 strong buy, 9 buy, 10 hold). Ratings are opinions, not guarantees; this is not investment advice.
How much is CRISPR Therapeutics expected to earn?
Analysts expect EPS of $-4.53 for the fiscal year ending December 31, 2026 and $-3.69 the year after.
Analyst consensus estimates and price targets, updated daily. Forecasts can be wrong; this is information, not investment advice.